NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
What's the purpose of the trial?
Accepting patients
Participating Centers
There are 24 centers participating in this trial. Enter a location below to find the closet center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Alectinib is a tyrosine kinase inhibitor for ALK (anaplastic lymphoma kinase) gene mutations.
- Atezolizumab is a new drug being tested in myeloma. It targets a protein called PDL-1 which is normally involved in dampening the immune response. This increases the activity of the immune system to recognize and destroy myeloma cells.
- Chemotherapy
- Cobimetinib
- Entrectinib is a first generation TRK inhibitor that is used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors.
- GDC-6036
- Pralsetinib
- Vemurafenib is a BRAF kinase inhibitor that is commonly used in the treatment of certain kinds of melanoma.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.